FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer

● REGULATORY

The FDA approved atezolizumab in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients two years and older with Stage III mismatch repair deficient colon cancer. Efficacy was evaluated in the ATOMIC/ML39057 trial, which showed a 50% reduction in risk of disease recurrence or death. (FDA)